Shares in Aspen Pharmacare reportedly jumped sharply on Monday after the South African drugmaker announced the sale of its Asia-Pacific operations outside China to Australian private equity firm BGH Capital for A$2.37 billion (approximately R26.5 billion).
The announcement sent Aspen’s stock soaring more than 20%, reflecting investor approval of a deal that delivers a premium valuation for assets the company had not originally planned to sell. By mid-morning, Aspen shares were trading 22% higher at R115.29 on the JSE, according to a BusinessDay report.
The transaction followed an unsolicited approach from BGH Capital and values the Asia-Pacific business at roughly 11 times forward earnings before interest, tax, depreciation, and amortisation (EBITDA). The assets being sold account for more than a quarter of Aspen’s annual EBITDA, making the disposal one of the group’s most significant strategic moves in recent years.
Beyond the valuation uplift, the sale is expected to substantially strengthen Aspen’s balance sheet. The proceeds will allow the company to reduce debt, streamline its lender base, and lower financing costs, while sharpening its strategic focus on higher-growth areas, including GLP-1 injectable therapies, a fast-expanding segment of the global pharmaceutical market.
The disposal includes Aspen’s operations in Australia, New Zealand, Hong Kong, Malaysia, Taiwan, and the Philippines. Its Australian and New Zealand businesses are among the top five over-the-counter pharmaceutical players in those markets. The deal also transfers ownership of the Dandenong manufacturing facility, which produces a wide range of pharmaceutical products, including tablets and capsules, as well as creams and liquid formulations.
Aspen said the sale was not part of a planned divestment programme, but that the boards of both Aspen and its subsidiary Aspen Global Incorporated assessed the unsolicited offer and concluded it represented compelling value for shareholders.
“Following a detailed assessment and careful consideration, the boards are of the view that the proposed transaction offers Aspen’s shareholders the opportunity to realise compelling value for Aspen APAC,” the company said, adding that shareholders will be advised to support the deal.
According to Aspen’s latest audited results, the Asia-Pacific business had net assets of about R23.2 billion as at June 30, 2025, underscoring the premium achieved through the sale.
The transaction remains subject to regulatory and shareholder approval, but analysts say it positions Aspen more favourably at a time when pharmaceutical companies across emerging markets are seeking to balance growth ambitions with tighter capital discipline.
For Africa’s largest pharmaceutical manufacturer, the deal marks a strategic pivot, trading scale in mature offshore markets for balance-sheet strength and a sharper focus on innovation-led growth.
